(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 December 2014 (04.12.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/194274 A2

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2014/040360

(22) International Filing Date:
30 May 2014 (30.05.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/829,082 30 May 2013 (30.05.2013) US

(71) Applicant: **BIOGEN IDEC MA INC.** [US/US]; 14 Cambridge Center, Massachusetts, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **ARNETT, Heather A.**; 3029 25th Avenue W., Seattle, Washington 98199 (US). **ESCOBAR, Sabine S.**; 1707 E. Beaver Lake Drive, SE, Sammamish, Washington 98075 (US). **KING, Chadwick T.**; 1325 Moody Avenue, North Vancouver, British Columbia V7L 3T5 (CA). **LIM, Ai Ching**; 7105 82nd Avenue, SE, Mercer Island, Washington 98040 (US). **NARAYANAN, Saravanakumar**; 70 Centre Street, #1C, Brookline, Massachusetts 02446 (US). **WEINREB, Paul H.**; 133 Boston Post Road, Weston, Massachusetts 02493 (US). **PEDERSON, Nels E.**; 71 Patty's Road, Mansfield, Massachusetts 02048 (US).

(74) Agents: **BRENNAN, Jack** et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2014/194274 A2

(54) Title: ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS

(57) Abstract: The invention provides anti-oncostatin M receptor-β (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.